// App-Quantinova.ai

: Outcomes with immune checkpoint inhibitor (ICI) therapy in patients with FGFR2/3 alterations in advanced urothelial carcinoma (aUC).

Researchers

Presenter

  • Rafee Talukder

Principal Investigators

  • Dimitrios Makrakis

  • Nishita Tripathi

  • Neeraj Agarwal

  • Tanya Jindal

  • Vadim S Koshkin

  • Jeffrey Johnson

  • Yousef Zakharia

  • Jason Brown

  • Macarena Rey-Cárdenas

  • Daniel Castellano

  • Ajjai Shivaram Alva

  • Roubini Zakopoulou

  • James Korolewicz

  • Alexandra Drakaki

  • Pedro C. Barata

  • Petros Grivas

  • Ali Raza Khaki

Medical Centers

  • UCLA, Los Angeles, CA

  • Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI

  • University of Washington, Seattle, WA

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • University of Iowa, Iowa City, IA

  • Department of Dermatology, University Hospitals Case Medical Center, Cleveland, OH

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Attikon Hospital, Athens, AZ, Greece

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Division of Oncology, Department of Medicine, University of Iowa, Iowa City, IA

  • Division of Hematology Oncology, Department of Medicine,University of California, San Diego,La Jolla,United States

  • Imperial College, London, United Kingdom

  • Servicio de Oncologia Medica. Hospital Universitario 12 de Octubre, Madrid, Spain

  • Hospital Universitario Doce de Octubre, Madrid, Spain

Locations

  • Greece

  • United Kingdom

  • Spain

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Fibroblast Growth Factor Receptor 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved